• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

FDA Pipeline preview, March 2009 (cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, omacetaxine)

Article

Recent FDA action (through March 2009) related to cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, and omacetaxine

sBLA withdrawn

• Cetuximab (Erbitux, Lilly/Bristol-Myers Squibb) for the treatment of advanced non-small cell lung cancer (NSCLC)

Complete response

• Iclaprim (Arpida) for the treatment of complicated skin and skin-structure infections

• Lasofoxifene (Pfizer) for the treatment of osteoporosis in postmenopausal women at increased risk of fracture

Recommended for approval

• Prasugrel (Daiichi Sankyo/Lilly) for the treatment of acute coronary syndromes (ACS) in patients managed with percutaneous coronary intervention (PCI)

• Ecallantide (DX-88, Dyax) for the treatment of acute attacks of hereditary angioedema (HAE)

Fast track designation

• Oral laquinimod (Teva/Active Biotech) for the treatment of relapsing-remitting multiple sclerosis (RRMS)

Priority review

• C1 inhibitor (human) (Cinryze, ViroPharma) for the treatment of acute attacks of HAE

Orphan drug designations

• SGN-35 (Seattle Genetics) for the treatment of anaplastic large cell lymphoma

• Omacetaxine (ChemGenex) for the treatment of myelodysplastic syndromes

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.